Contrasting Coeptis Therapeutics (NASDAQ:ZSQR) & PagerDuty (NYSE:PD)

PagerDuty (NYSE:PD) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Volatility & Risk

PagerDuty has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500.

Insider & Institutional Ownership

97.3% of PagerDuty shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 6.0% of PagerDuty shares are owned by insiders. Comparatively, 24.2% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares PagerDuty and Coeptis Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PagerDuty	37.50%	18.52%	4.84%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

Analyst Ratings

This is a summary of recent ratings and target prices for PagerDuty and Coeptis Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PagerDuty	2	5	3	0	2.10
Coeptis Therapeutics	1	0	0	0	1.00

PagerDuty currently has a consensus price target of $12.56, indicating a potential downside of 12.73%. Given PagerDuty’s stronger consensus rating and higher possible upside, equities research analysts clearly believe PagerDuty is more favorable than Coeptis Therapeutics.

Earnings & Valuation

This table compares PagerDuty and Coeptis Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PagerDuty	$494.73 million	2.29	$173.85 million	$2.00	7.20
Coeptis Therapeutics	$1.36 million	147.31	-$11.92 million	($1.63)	-2.32

PagerDuty has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than PagerDuty, indicating that it is currently the more affordable of the two stocks.

Summary

PagerDuty beats Coeptis Therapeutics on 12 of the 14 factors compared between the two stocks.

About PagerDuty

PagerDuty, Inc. engages in the operation of a digital operations management platform in the United States and internationally. The company’s digital operations management platform collects data and digital signals from virtually any software-enabled system or device and leverage machine learning to correlate, process, and predict opportunities and issues. Its platform includes PagerDuty Incident Management that provides a real-time view across the status of a digital service while incorporating noise reduction to remove false positives; AIOps that applies machine learning to correlate and automate the identification of incidents from billions of events; Process Automation offers centralized design time and run time environment for orchestrating automated workflows that span across departments, technologies, and networks; Customer Service Operations, which is offered to orchestrate, automate, and scale responses to customer impacting issues. It serves various industries, including software and technology, telecommunications, retail, travel and hospitality, media and entertainment, and financial services. PagerDuty, Inc. was founded in 2009 and is headquartered in San Francisco, California.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.